Mobile

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Canc...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-001641-89

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine a difference in PFS by an Independent Review Committee (IRC) between lurbinectedin (PM01183)/DOX and a control arm consisting of best Investigator’s choice between CTX, DOX and VCR (CAV) or topotecan, as treatment in SCLC patients after failure of one prior platinum-containing line

Critère d'inclusion

  • Small cell lung cancer (SCLC)